ライフサイエンスコーパス: genital lesion

1 . haematobium and a dynamic evolution of the genital lesions.

2 tients received the same local treatment for genital lesions.

3 s greatly reduced the frequency of recurrent genital lesions.

4 sing clinically indistinguishable facial and genital lesions.

5 x acts occurring when the source partner had genital lesions.

6 tudinally track these clonotypes in PBMC and genital lesions.

7 ermine the specific HPV types present in the genital lesions.

8 nts, both HSV-1 and HSV-2 was recovered from genital lesions.

9 marily from sacral ganglia causing recurrent genital lesions.

10 ductions in the frequency of HSV shedding or genital lesions.

11 67 immunocompetent individuals with measured genital lesion and HSV shedding rates.

12 Fifty percent of patients had grade I genital lesions and 50% had grade II or III lesions.

13 nfection presented as a prolonged episode of genital lesions and a marked increase in the frequency o

14 cy in preventing the development of external genital lesions and anogenital HPV infection in boys and

15 A herpes vaccine that prevents genital lesions and asymptomatic genital shedding will h

16 ein C (gC2) and glycoprotein D (gD2) reduced genital lesions and asymptomatic HSV-2 genital shedding

17 The animals develop genital lesions and fully recover.

18 on was associated with a reduced severity of genital lesions and lower levels of viral shedding in th

19 f HSV in positive swabs and the frequency of genital lesions and shedding episodes.

20 a sexually transmitted pathogen that causes genital lesions and spreads to the nervous system to est

21 emed to prevent further evolution of grade I genital lesions and to avoid surgical treatment.

22 ers and improved survival but did not reduce genital lesions and viral shedding.

23 gD2t-alum-MPL improved survival and reduced genital lesions and viral shedding.

24 se, vaginal titers, DRG infection, recurrent genital lesions, and recurrent vaginal shedding of HSV-2

25 areas for HSV culture, maintained a diary of genital lesions, and were examined at the time of recurr

26 were detected in all biopsies, together with genital lesion-associated HPV types 6, 16, and 52, (as w

27 types 6, 16, and 52, (as well as >/=3 other genital lesion-associated HPV types).

28 tomatic HSV-2 seroconversion, 15 percent had genital lesions at some time during follow-up.

29 difference is attributable to less frequent genital lesions because lesions are accompanied by frequ

30 rated HIV-1 DNA in cells derived from healed genital lesion biopsies than in cells from control skin

31 hogenic agent that causes recurrent oral and genital lesions, blindness and encephalitis.

32 ivity was assessed by testing 112 ulcerative genital lesions by the HC II assay and comparing the res

33 Genital lesions consistent with exophytic condylomata ac

34 Although genital lesions developed in some UL24-betagluc-inoculat

35 Human papillomavirus (HPV) causes external genital lesions (EGLs) in men, including condyloma and p

36 wice daily for HSV-2 detection and monitored genital lesions for 28-day periods at baseline and at in

37 d 18 and the development of related external genital lesions in males 16 to 26 years of age.

38 ex viruses (HSV) cause painful cold sores or genital lesions in many people; less often, they affect

39 f people worldwide, causing painful oral and genital lesions, in addition to a multitude of more seve

40 edicted peak HSV DNA copy number and whether genital lesions or subclinical shedding occurred.

41 PV vaccine reduced the incidence of external genital lesions related to HPV-6, 11, 16, or 18.

42 ng (RR, 1.7 [95% CI, 1.1-2.7]; P = .01), and genital lesions (RR, 2.1 [95% CI, 1.2-3.4]; P = .005), c

43 HIV-1 RNA in genital lesion swabs was seen in persons with high and l

44 we examined the women with a colposcope for genital lesions, tested endocervical specimens for gonor

45 The percentage of days with genital lesions was also significantly reduced, from 9.0

46 f HSV-specific CD4(+) cells that localize to genital lesions, we developed a sensitive and highly spe

47 The rates of genital lesions were 42.2 cases per 100 woman-years in t

48 The rates of recurrence of genital lesions were normal for recombinant viruses 524

49 d HSV-2 episodes and on 67% of days in which genital lesions were noted.

50 Genital lesions were present on 1.9% of days in the prit

51 Genital lesions were reported on 749 of 3875 days (19%),

52 e intention-to-treat population, 36 external genital lesions were seen in the vaccine group as compar

53 ogens significantly reduced the frequency of genital lesions, with the bivalent vaccine showing the g